SCHEMBL12216699

SCHEMBL12216699

O=[N+]([O-])c1ccc(-[n+]2ccc(-c3cc[n+](-c4ccccc4)cc3)cc2)c([N+](=O)[O-])c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
ATM Q13315 1/20 0.60
ALDH1A1 P00352 4/20 0.43
MAPK1 P28482 3/20 0.43
HIF1A Q16665 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
CRHBP P24387 3/20 0.42
CRHR2 Q13324 3/20 0.42
CES2 O00748 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
GPR35 Q9HC97 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29618182 0.93 RAB9A (0.64) NPC1RAB9AATMALDH1A1MAPK1
SCHEMBL13648647 0.93 RAB9A (0.64) NPC1RAB9AATMALDH1A1MAPK1
Hydrochloric Acid SCHEMBL8068701 0.92 NPC1 (0.67) NPC1RAB9AATMALDH1A1MAPK1
SCHEMBL11694301 0.90 NPC1 (0.62) NPC1RAB9AATMALDH1A1MAPK1
Hydrochloric Acid SCHEMBL599994 0.88 NPC1 (0.65) NPC1RAB9AATMALDH1A1MAPK1
Bromide SCHEMBL5144105 0.88 NPC1 (0.61) NPC1RAB9AATMALDH1A1MAPK1
Hydrochloric Acid SCHEMBL30343291 0.88 NPC1 (0.65) NPC1RAB9AATMALDH1A1MAPK1
SCHEMBL741714 0.84 NPC1 (0.62) NPC1RAB9AATMALDH1A1MAPK1
SCHEMBL30109383 0.83 ALDH1A1 (0.54) NPC1RAB9AATMALDH1A1MAPK1
SCHEMBL5156780 0.83 NPC1 (0.56) NPC1RAB9AATMALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039630-B2 Cationic compound, dye compound and method of using the same, and optical information recording medium FUJIFILM CORPORATION (JP) 2011-10-18 US disclosed
US-8039630-B2 Cationic compound, dye compound and method of using the same, and optical information recording medium FUJIFILM CORPORATION (JP) 2011-10-18 US disclosed
US-20090130367-A1 CATIONIC COMPOUND, DYE COMPOUND AND METHOD OF USING THE SAME, AND OPTICAL INFORMATION RECORDING MEDIUM FUJIFILM CORPORATION (JP) 2009-05-21 US disclosed
US-20090130367-A1 CATIONIC COMPOUND, DYE COMPOUND AND METHOD OF USING THE SAME, AND OPTICAL INFORMATION RECORDING MEDIUM FUJIFILM CORPORATION (JP) 2009-05-21 US disclosed
US-20090082570-A1 METHOD OF MANUFACTURING BIPYRIDINIUM COMPOUND AND SYNTHETIC INTERMEDIATE OF THE SAME, METHOD OF MANUFACTURING DYE COMPOUND, AND NOVEL BIPYRIDINIUM COMPOUND AND NOVEL DYE COMPOUND COMPRISING THE SAME FUJIFILM CORPORATION (JP) 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082570-A1 METHOD OF MANUFACTURING BIPYRIDINIUM COMPOUND AND SYNTHETIC INTERMEDIATE OF THE SAME, METHOD OF MANUFACTURING DYE COMPOUND, AND NOVEL BIPYRIDINIUM COMPOUND AND NOVEL DYE COMPOUND COMPRISING THE SAME RRS1, RPS3, ADRM1 NPC1 4058/4885RAB9A 1314/4885ATM 1962/4885
US-20090130367-A1 CATIONIC COMPOUND, DYE COMPOUND AND METHOD OF USING THE SAME, AND OPTICAL INFORMATION RECORDING MEDIUM CHRM1, CHRM2, TRPC6 NPC1 2177/4885RAB9A 2541/4885ATM 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.